Table 2.

Therapy

	Background Therapy (n = 84)	Subsequent Therapy (n = 129)
Treatment naive (n = 45)		Of 45 patients:
		24 (53) PDE5I
		8 (18) ERA
		5 (11) CCB
		2 (4) PROST
		4 (9) PDE5I and ERA
		1 (2) PROST and ERA
		1 (2) diuretics alone
Background therapy	Of 84 patients:	Of 84 patients:
	23 (27) PDE5I	8 (10) PDE5I
	19 (23) ERA	13 (15) ERA
	11 (13) PROST	12 (14) PROST
	16 (19) PDE5I and ERA	3 (3) PDE5I and ERA
	10 (12) PDE5I and PROST	1 (1) PDE5I and PROST
	1 (1) PROST and ERA	2 (2) PROST and ERA
	4 (5) PDE5I, ERA, PROST	0 PDE5I, ERA, PROST
		21 (25) PAH therapy dose change
		6 (8) Behavioral modifications
		9 (11) Adjustment in non-PAH therapy
		9 (11) Enrollment in clinical trials or PR

Definition of abbreviations: CCB = calcium channel blocker; ERA = endothelin receptor antagonist; PAH = pulmonary arterial hypertension; PDE5I = phosphodiesterase type 5 inhibitor; PR = pulmonary rehabilitation; PROST = prostacyclin.

Data presented as n (%).